全文获取类型
收费全文 | 194篇 |
免费 | 7篇 |
出版年
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 3篇 |
2018年 | 8篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 17篇 |
2014年 | 13篇 |
2013年 | 13篇 |
2012年 | 22篇 |
2011年 | 23篇 |
2010年 | 11篇 |
2009年 | 8篇 |
2008年 | 9篇 |
2007年 | 10篇 |
2006年 | 9篇 |
2005年 | 11篇 |
2004年 | 7篇 |
2003年 | 2篇 |
2002年 | 5篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1982年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有201条查询结果,搜索用时 31 毫秒
71.
Evripidis Kaltsonoudis Anastasia K Zikou Paraskevi V Voulgari Spyridon Konitsiotis Maria I Argyropoulou Alexandros A Drosos 《Arthritis research & therapy》2014,16(3):R125
Introduction
The aim was to investigate the frequency of neurological adverse events in patients with rheumatoid arthritis (RA) and spondylarthropathies (SpA) treated with tumor necrosis factor (TNF) α antagonists.Methods
Seventy-seven patients eligible for anti-TNFα therapy were evaluated. There were 36 patients with RA, 41 with SpA [24 psoriatic arthritis (PsA) and 17 with ankylosing spondylitis (AS)]. All patients had a complete physical and neurological examination. Brain and cervical spine magnetic resonance imaging (MRI) and neurophysiological tests were performed in all patients before the initiation of anti-TNFα therapy and after a mean of 18 months or when clinical symptoms and signs indicated a neurological disease. Exclusion criteria included hypertension, diabetes mellitus, dyslipidemia, heart arrhythmias, atherothrombotic events, vitamin B12 and iron deficiency, head and neck trauma and neurological surgeries.Results
Two patients did not receive anti-TNFα therapy because brain MRIs at baseline revealed lesions compatible with demyelinating diseases. Thus, 75 patients received anti-TNFα (38 infliximab, 19 adalimumab and 18 etanercept). Three patients developed neurological adverse events. A 35-year-old man with PsA after 8 months of infliximab therapy presented with paresis of the left facial nerve and brain MRI showed demyelinating lesions. Infliximab was discontinued and he was treated with pulses of corticosteroids recovering completely after two months. The second patient was a 45-year-old woman with RA who after 6 months of adalimumab therapy presented with optic neuritis. The third patient was a 50-year-old woman with AS, whom after 25 months of infliximab therapy, presented with tingling and numbness of the lower extremities and neurophysiological tests revealed peripheral neuropathy. In both patients anti-TNF were discontinued and they improved without treatment after 2 months. The rest of our patients showed no symptoms and MRIs showed no abnormalities. The estimated rate of neurological adverse events in patients treated with anti-TNF therapy is 4% (3/75).Conclusions
Neurological adverse events after anti-TNFα therapy were observed in our patient. Brain MRI and neurophysiological tests are essential tools to discriminate neurological diseases. 相似文献72.
Håvik B Degenhardt FA Johansson S Fernandes CP Hinney A Scherag A Lybæk H Djurovic S Christoforou A Ersland KM Giddaluru S O'Donovan MC Owen MJ Craddock N Mühleisen TW Mattheisen M Schimmelmann BG Renner T Warnke A Herpertz-Dahlmann B Sinzig J Albayrak Ö Rietschel M Nöthen MM Bramham CR Werge T Hebebrand J Haavik J Andreassen OA Cichon S Steen VM Le Hellard S 《PloS one》2012,7(4):e35424
Doublecortin and calmodulin like kinase 1 (DCLK1) is implicated in synaptic plasticity and neurodevelopment. Genetic variants in DCLK1 are associated with cognitive traits, specifically verbal memory and general cognition. We investigated the role of DCLK1 variants in three psychiatric disorders that have neuro-cognitive dysfunctions: schizophrenia (SCZ), bipolar affective disorder (BP) and attention deficit/hyperactivity disorder (ADHD). We mined six genome wide association studies (GWASs) that were available publically or through collaboration; three for BP, two for SCZ and one for ADHD. We also genotyped the DCLK1 region in additional samples of cases with SCZ, BP or ADHD and controls that had not been whole-genome typed. In total, 9895 subjects were analysed, including 5308 normal controls and 4,587 patients (1,125 with SCZ, 2,496 with BP and 966 with ADHD). Several DCLK1 variants were associated with disease phenotypes in the different samples. The main effect was observed for rs7989807 in intron 3, which was strongly associated with SCZ alone and even more so when cases with SCZ and ADHD were combined (P-value = 4 × 10(-5) and 4 × 10(-6), respectively). Associations were also observed with additional markers in intron 3 (combination of SCZ, ADHD and BP), intron 19 (SCZ+BP) and the 3'UTR (SCZ+BP). Our results suggest that genetic variants in DCLK1 are associated with SCZ and, to a lesser extent, with ADHD and BP. Interestingly the association is strongest when SCZ and ADHD are considered together, suggesting common genetic susceptibility. Given that DCLK1 variants were previously found to be associated with cognitive traits, these results are consistent with the role of DCLK1 in neurodevelopment and synaptic plasticity. 相似文献
73.
74.
75.
76.
77.
78.
Vassiliki Kati Paraskevi Mani Otto von Helversen Fer Willemse Norbert Elsner Panayotis Dimopoulos 《Journal of Insect Conservation》2006,10(1):65-74
Chorthippus lacustris is an endemic grasshopper (Orthoptera) species in Epirus, Greece. Its population status, habitat characteristics, and relation
to historical and current human land use are investigated. The species has a restricted and fragmented distribution pattern.
Five locations, four within Pamvotida Lake basin and one in Lake Paramythia, cover a total of 0.12 km2. It is strongly dependent on wet grasslands, flooded on a seasonal basis. The greatest population density is recorded in
the site with the greatest diversity of dominant plant species. Ch. lacustris is estimated to have lost 85–99% of its habitat during the last 50 years due to wetland drainage. The main threat to the
species survival is further habitat loss by urbanisation around Pamvotida Lake and by land conversion to agriculture in Paramythia
Lake, even though both sites belong to the Natura 2000 network. The species status is Critically Endangered and it should
be listed in Annex II of the Habitat Directive (92/43/EEC) as a priority species for conservation. Restoring wet grasslands,
protecting them from further urbanisation and drainage, and monitoring species population are the main measures proposed for
its conservation. 相似文献
79.
Paraskevi Gkeka Thomas Evangelidis Maria Pavlaki Vasiliki Lazani Savvas Christoforidis Bogos Agianian Zoe Cournia 《PLoS computational biology》2014,10(10)
The PIK3CA gene is one of the most frequently mutated oncogenes in human cancers. It encodes p110α, the catalytic subunit of phosphatidylinositol 3-kinase alpha (PI3Kα), which activates signaling cascades leading to cell proliferation, survival, and cell growth. The most frequent mutation in PIK3CA is H1047R, which results in enzymatic overactivation. Understanding how the H1047R mutation causes the enhanced activity of the protein in atomic detail is central to developing mutant-specific therapeutics for cancer. To this end, Surface Plasmon Resonance (SPR) experiments and Molecular Dynamics (MD) simulations were carried out for both wild-type (WT) and H1047R mutant proteins. An expanded positive charge distribution on the membrane binding regions of the mutant with respect to the WT protein is observed through MD simulations, which justifies the increased ability of the mutated protein variant to bind to membranes rich in anionic lipids in our SPR experiments. Our results further support an auto-inhibitory role of the C-terminal tail in the WT protein, which is abolished in the mutant protein due to loss of crucial intermolecular interactions. Moreover, Functional Mode Analysis reveals that the H1047R mutation alters the twisting motion of the N-lobe of the kinase domain with respect to the C-lobe and shifts the position of the conserved P-loop residues in the vicinity of the active site. These findings demonstrate the dynamical and structural differences of the two proteins in atomic detail and propose a mechanism of overactivation for the mutant protein. The results may be further utilized for the design of mutant-specific PI3Kα inhibitors that exploit the altered mutant conformation. 相似文献
80.
Radoslaw Debiec Paraskevi Christofidou Matthew Denniff Lisa D. Bloomer Pawel Bogdanski Lukasz Wojnar Katarzyna Musialik Fadi J. Charchar John R. Thompson Dawn Waterworth Kijoung Song Peter Vollenweider Gerard Waeber Ewa Zukowska-Szczechowska Nilesh J. Samani David Lambert Maciej Tomaszewski 《PloS one》2013,8(12)
Urotensin-II controls ion/water homeostasis in fish and vascular tone in rodents. We hypothesised that common genetic variants in urotensin-II pathway genes are associated with human blood pressure or renal function. We performed family-based analysis of association between blood pressure, glomerular filtration and genes of the urotensin-II pathway (urotensin-II, urotensin-II related peptide, urotensin-II receptor) saturated with 28 tagging single nucleotide polymorphisms in 2024 individuals from 520 families; followed by an independent replication in 420 families and 7545 unrelated subjects. The expression studies of the urotensin-II pathway were carried out in 97 human kidneys. Phylogenetic evolutionary analysis was conducted in 17 vertebrate species. One single nucleotide polymorphism (rs531485 in urotensin-II gene) was associated with adjusted estimated glomerular filtration rate in the discovery cohort (p = 0.0005). It showed no association with estimated glomerular filtration rate in the combined replication resource of 8724 subjects from 6 populations. Expression of urotensin-II and its receptor showed strong linear correlation (r = 0.86, p<0.0001). There was no difference in renal expression of urotensin-II system between hypertensive and normotensive subjects. Evolutionary analysis revealed accumulation of mutations in urotensin-II since the divergence of primates and weaker conservation of urotensin-II receptor in primates than in lower vertebrates. Our data suggest that urotensin-II system genes are unlikely to play a major role in genetic control of human blood pressure or renal function. The signatures of evolutionary forces acting on urotensin-II system indicate that it may have evolved towards loss of function since the divergence of primates. 相似文献